<div id="readability-page-1"><p>Analyst Ritu Baral from TD Cowen maintained a Buy rating on Vera Therapeutics and keeping the price target at $73.00.</p><h3>Claim 55% Off TipRanks</h3><ul><li>Unlock  hedge fund-level data  and  powerful investing tools  for smarter, sharper decisions  </li><li> Discover top-performing stock ideas and upgrade to a portfolio of market leaders with  Smart Investor Picks  </li></ul> <p>Ritu Baral has given his Buy rating due to a combination of factors, foremost among them the strong regulatory and clinical positioning of atacicept in IgA nephropathy. The drug has secured a priority-review PDUFA date of July 7, and the BLA is backed by Phase 3 data showing a meaningful and statistically significant reduction in proteinuria versus placebo, supporting expectations for a relatively clean approval and competitive labeling.</p> <p>Ritu Baral’s rating is based on Vera’s commercial readiness and financial runway, which together de-risk the launch execution. Management is building a focused nephrology sales force to cover a majority of U.S. nephrologists, and pricing is likely to be comparable to a high benchmark set by a recently launched competitor, implying attractive revenue potential. In addition, a solid cash position provides operating runway beyond the expected approval and launch, allowing the company to advance further data readouts and lifecycle expansion without near-term financing pressure. The price target is unchanged at $73, reflecting the favorable risk‑reward profile.</p> <p>According to TipRanks, Baral is a top 100 analyst with an average return of <span>47.8%</span> and a 55.67% success rate. Baral covers the Healthcare sector, focusing on stocks such as COMPASS Pathways, Praxis Precision Medicines, and ACADIA Pharmaceuticals.</p> <p>In another report released yesterday, LifeSci Capital also maintained a Buy rating on the stock with a $90.00 price target.</p></div>

VERA

<p>Analyst Ritu Baral from TD Cowen has reiterated a Buy rating on Vera Therapeutics, maintaining a price target of $73. The positive outlook is driven by the strong regulatory and clinical positioning of atacicept for IgA nephropathy, with a priority-review PDUFA date set for July 7. The company is preparing for launch with a focused nephrology sales force and a solid cash position, ensuring operational stability. LifeSci Capital also supports the stock with a Buy rating and a $90 price target.</p>

Tip Ranks

Vera Therapeutics

Invesco Biotechnology & Genome ETF

VanEck Biotech ETF

VG Health

SPDR S&P Biotech

Health Care Select Sector SPDR

iShares US Pharma

Invesco Nasdaq Biotechnology ETF

iShares Biotechnology ETF

iShares Global Healthcare

Ark Genomic Revolution ETF

Proshares Ultra Nasdaq Biotech

ALPS Medical Breakthrough

First Trust NYSE Arca Biotech Index Fd

Direxion S&P Biotech Bull 3X

Toronto Dominion Bank

Compass Pathways

Praxis Precision Medicines

Acadia Pharma

Vera Therapeutics: Buy Rating Reiterated on Strong Atacicept Outlook and Launch Readiness; $73 Price Target Maintained